{"url_path":"/sec/tmdx/8-k/2026-05-21/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/1756262/0001193125-26-234440-index.html","accession_number":"0001193125-26-234440","cik":"0001756262","ticker":"TMDX","issuer_name":"TransMedics Group, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1756262/0001193125-26-234440-index.html","primary_entity_key":"0001756262","primary_entity_name":"TransMedics Group, Inc."},"word_count":296,"has_tables":true,"body_markdown":"Item 5.07\n\nSubmission of Matters to a Vote of Security Holders.\n\nOn May 20, 2026, TransMedics Group, Inc. (the “Company”) held its 2026 Annual Meeting of Shareholders (the “Annual Meeting”). At the Annual Meeting, the shareholders of the Company voted on the following proposals:\n\nProposal One: The shareholders elected Waleed Hassanein, M.D., James R. Tobin, Edward M. Basile, Thomas J. Gunderson, Edwin M. Kania, Jr., Stephanie Lovell, Merilee Raines, and David Weill, M.D. as directors, each to serve on the Board of Directors of the Company until the 2027 Annual Meeting of Shareholders or until his or her successor is duly elected and qualified in accordance with our Restated Articles of Organization and Amended and Restated Bylaws, or his or her earlier death, resignation or removal, based on the following votes:\n\n \n\nDirector Nominee\n  \nFor\n \n  \nAgainst\n \n  \nAbstain\n \n  \nBroker\nNon-Votes\n \n\nWaleed Hassanein, M.D\n\n  \n \n23,925,335\n \n  \n \n122,999\n \n  \n \n15,389\n \n  \n \n4,632,985\n \n\nJames R. Tobin\n\n  \n \n23,594,322\n \n  \n \n453,100\n \n  \n \n16,301\n \n  \n \n4,632,985\n \n\nEdward M. Basile\n\n  \n \n22,395,787\n \n  \n \n1,651,466\n \n  \n \n16,470\n \n  \n \n4,632,985\n \n\nThomas J. Gunderson\n\n  \n \n23,667,347\n \n  \n \n380,233\n \n  \n \n16,143\n \n  \n \n4,632,985\n \n\nEdwin M. Kania, Jr.\n\n  \n \n23,603,708\n \n  \n \n443,438\n \n  \n \n16,577\n \n  \n \n4,632,985\n \n\nStephanie Lovell\n\n  \n \n23,932,921\n \n  \n \n111,757\n \n  \n \n19,045\n \n  \n \n4,632,985\n \n\nMerilee Raines\n\n  \n \n23,908,647\n \n  \n \n140,715\n \n  \n \n14,361\n \n  \n \n4,632,985\n \n\nDavid Weill, M.D.\n\n  \n \n23,842,978\n \n  \n \n204,717\n \n  \n \n16,028\n \n  \n \n4,632,985\n \n\nProposal Two: The shareholders approved, on a non-binding advisory basis, the compensation paid to the Company’s named executive officers, based on the following votes:\n\n \n\nFor\n\n \n\nAgainst\n\n \n\nAbstain\n\n \n\nBroker Non-Votes\n\n22,871,647\n \n1,161,181\n \n30,895\n \n4,632,985\n\nProposal Three: The shareholders approved the amendment to the Amended and Restated TransMedics Group, Inc. 2019 Stock Incentive Plan, based on the following votes:\n\n \n\nFor\n\n \n\nAgainst\n\n \n\nAbstain\n\n \n\nBroker Non-Votes\n\n17,265,369\n \n6,758,882\n \n39,472\n \n4,632,985\n\nProposal Four: The shareholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2026, based on the following votes:\n\n \n\nFor\n\n \n\nAgainst\n\n \n\nAbstain\n\n28,030,696\n \n648,359\n \n17,653"}